Merger activity decreased last week with two new deals announced and six pending deals closing.
Deal Statistics:
New Deals:
- The acquisition of Clementia Pharmaceuticals (CMTA) by Ipsen for $1.31 billion. Under the terms of the agreement, shareholders of Clementia Pharmaceuticals will receive $25.00 per share in cash upfront plus deferred payments in the form of a contingent value right (CVR) of $6.00 per share upon FDA acceptance of the NDA filing for the late-stage drug palovarotene.
- The acquisition of Multi-Color Corporation (LABL) by an affiliate of Platinum Equity for